In a report published by Rao et al in Morbidity and Mortality Weekly Report, investigators provided interim clinical considerations to assist in medical countermeasure decision-making for patients with severe manifestations of mpox. The authors cover the use of antivirals (tecovirimat, brincidofovir, cidofovir, and trifluridine ophthalmic solution) and vaccinia immune globulin intravenous; their indications for use; development of a management algorithm to use effective medial countermeasures; and common issues seen in severe infections, such as ocular infections, neurologic complications, myopericarditis, mucosal lesion complications, and uncontrolled viral spread.
May 24, 2023